Abstract
• With several newly approved regimens for RCC, cardiovascular risks must be considered during treatment selection. • Although uncommon, toxicities associated with these systemic therapies can have shortterm and long-term implications. • Although some toxicities may be lethal, others can be managed with early intervention. • As further agents are developed, multidisciplinary expertise is needed to manage associated cardiovascular toxicities.